107 related articles for article (PubMed ID: 12087588)
21. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
Markowitz GS; Appel GB; Fine PL; Fenves AZ; Loon NR; Jagannath S; Kuhn JA; Dratch AD; D'Agati VD
J Am Soc Nephrol; 2001 Jun; 12(6):1164-1172. PubMed ID: 11373339
[TBL] [Abstract][Full Text] [Related]
22. Toxic acute tubular necrosis following treatment with zoledronate (Zometa).
Markowitz GS; Fine PL; Stack JI; Kunis CL; Radhakrishnan J; Palecki W; Park J; Nasr SH; Hoh S; Siegel DS; D'Agati VD
Kidney Int; 2003 Jul; 64(1):281-9. PubMed ID: 12787420
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
Grewal VS; Fayans EP
Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
[TBL] [Abstract][Full Text] [Related]
24. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
25. [Langerhans cell histiocytosis].
Ben Slama L; Ruhin B; Zoghbani A
Rev Stomatol Chir Maxillofac; 2009 Nov; 110(5):287-9. PubMed ID: 19828161
[TBL] [Abstract][Full Text] [Related]
26. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure.
Monney P; Nguyen QV; Perroud H; Descombes E
Nephrol Dial Transplant; 2004 Aug; 19(8):2130-2. PubMed ID: 15252173
[No Abstract] [Full Text] [Related]
27. The use of pamidronate in three children with renal disease.
Sellers E; Sharma A; Rodd C
Pediatr Nephrol; 1998 Nov; 12(9):778-81. PubMed ID: 9874327
[TBL] [Abstract][Full Text] [Related]
28. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept?
Sauter M; Jülg B; Porubsky S; Cohen C; Fischereder M; Sitter T; Schlondorff D; Gröne HJ
Am J Kidney Dis; 2006 Jun; 47(6):1075-80. PubMed ID: 16731304
[No Abstract] [Full Text] [Related]
29. Acute renal failure and nephrotic syndrome after maneb exposure. A new case with light and electron microscopic study.
de Carvalho E; Faria V; Loureiro A; Miranda V
Acta Med Port; 1989; 2(4-5):215-8. PubMed ID: 2618810
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonate nephrotoxicity.
Perazella MA; Markowitz GS
Kidney Int; 2008 Dec; 74(11):1385-93. PubMed ID: 18685574
[TBL] [Abstract][Full Text] [Related]
31. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
[TBL] [Abstract][Full Text] [Related]
32. Nephrotic syndrome, renal insufficiency, and a monoclonal gammopathy.
Markowitz GS; Zdunek MP; D'Agati VD
Am J Kidney Dis; 2001 Nov; 38(5):1135-40. PubMed ID: 11684573
[No Abstract] [Full Text] [Related]
33. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
[TBL] [Abstract][Full Text] [Related]
34. Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis.
Toussirot E; Wendling D
Curr Opin Rheumatol; 2007 Jul; 19(4):340-5. PubMed ID: 17551363
[TBL] [Abstract][Full Text] [Related]
35. Nephrotic syndrome revealing a disseminated Langerhans' cell histiocytosis.
Anabi A; Tarrass F; Hachim K; Aghai R; Benghanem MG; Ramdani B; Zaid D; El Attar H; Badr L; Sqalli S
J Nephrol; 2005; 18(6):777-80. PubMed ID: 16358239
[TBL] [Abstract][Full Text] [Related]
36. Osteonecrosis of the jaw associated with pamidronate therapy.
Zarychanski R; Elphee E; Walton P; Johnston J
Am J Hematol; 2006 Jan; 81(1):73-5. PubMed ID: 16369966
[TBL] [Abstract][Full Text] [Related]
37. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy.
Perazella MA; Moeckel GW
Semin Nephrol; 2010 Nov; 30(6):570-81. PubMed ID: 21146122
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
[TBL] [Abstract][Full Text] [Related]
39. Reversible renal failure and nephrotic syndrome associated with nonsteroidal anti-inflammatory drugs.
Brezin JH; Katz SM; Schwartz AB; Chinitz JL
N Engl J Med; 1979 Dec; 301(23):1271-3. PubMed ID: 503131
[No Abstract] [Full Text] [Related]
40. Pamidronate-induced nephrotoxic tubular necrosis--a case report.
Smetana S; Michlin A; Rosenman E; Biro A; Boaz M; Katzir Z
Clin Nephrol; 2004 Jan; 61(1):63-7. PubMed ID: 14964460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
